A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

Inclusion Criteria: * Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Subjects with tumors specified below, who are at high risk of relapse, have been treated with curative intent, and have no evidence of disease (NED) following front-line therapy with surgery, radiation therapy, and/or chemotherapy. NED includes, where applicable, surgical (macroscopic tumor margin, at the time of surgery), and radiological evidence of disease. Residual lesions identified by microscopic/frozen margins and biochemical markers are permitted. Therapy must have been completed no fewer than four weeks, and no later than 25 weeks, before the first dose of Ad5.F35-hGCC-PADRE * For tumor-specific criteria, please refer to the information below: \* Pancreatic ductal adenocarcinoma \*\* Stage I, II, III * Neuroendocrine tumors of the pancreas are not permitted \* Colorectal adenocarcinoma * Stage III; stage IV following metastasectomy \* Gastric adenocarcinoma * Stage IIA, IIB, III * Gastrointestinal stromal tumors of the stomach are not permitted \* Esophageal adenocarcinoma \*\* Stage IIB, III * Esophageal squamous cell carcinomas are not permitted * Have an anticipated life expectancy of greater than 12 weeks * Absolute neutrophil count (ANC) \>= 1000 cells/mL * Platelets \>= 75,000 /mL * Hemoglobin \>= 9.0 g/dL * Serum creatinine \< 2.0 mg/dL * For other blood and urine tests including blood chemistry, hepatic and renal funct…